Try a new search

Format these results:

Searched for:

in-biosketch:yes

person:keatib01

Total Results:

203


Genetic analysis of impaired trimethylamine metabolism using whole exome sequencing

Guo, Yiran; Hwang, Liang-Dar; Li, Jiankang; Eades, Jason; Yu, Chung Wen; Mansfield, Corrine; Burdick-Will, Alexis; Chang, Xiao; Chen, Yulan; Duke, Fujiko F; Zhang, Jianguo; Fakharzadeh, Steven; Fennessey, Paul; Keating, Brendan J; Jiang, Hui; Hakonarson, Hakon; Reed, Danielle R; Preti, George
BACKGROUND:Trimethylaminuria (TMAU) is a genetic disorder whereby people cannot convert trimethylamine (TMA) to its oxidized form (TMAO), a process that requires the liver enzyme FMO3. Loss-of-function variants in the FMO3 gene are a known cause of TMAU. In addition to the inability to metabolize TMA precursors like choline, patients often emit a characteristic odor because while TMAO is odorless, TMA has a fishy smell. The Monell Chemical Senses Center is a research institute with a program to evaluate people with odor complaints for TMAU. METHODS:Here we evaluated ten subjects by (1) odor evaluation by a trained sensory panel, (2) analysis of their urine concentration of TMA relative to TMAO before and after choline ingestion, and (3) whole exome sequencing as well as subsequent variant analysis of all ten samples to investigate the genetics of TMAU. RESULTS:While all subjects reported they often emitted a fish-like odor, none had this malodor during sensory evaluation. However, all were impaired in their ability to produce >90% TMAO/TMA in their urine and thus met the criteria for TMAU. To probe for genetic causes, the exome of each subject was sequenced, and variants were filtered by genes with a known (FMO3) or expected effect on TMA metabolism function (other oxidoreductases). We filtered the remaining variants by allele frequency and predicated functional effects. We identified one subject that had a rare loss-of-function FMO3 variant and six with more common decreased-function variants. In other oxidoreductases genes, five subjects had four novel rare single-nucleotide polymorphisms as well as one rare insertion/deletion. Novel in this context means no investigators have previously linked these variants to TMAU although they are in dbSNP. CONCLUSIONS:Thus, variants in genes other than FMO3 may cause TMAU and the genetic variants identified here serve as a starting point for future studies of impaired TMA metabolism.
PMCID:5310055
PMID: 28196478
ISSN: 1471-2350
CID: 5478562

PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study

Schmidt, Amand F; Swerdlow, Daniel I; Holmes, Michael V; Patel, Riyaz S; Fairhurst-Hunter, Zammy; Lyall, Donald M; Hartwig, Fernando Pires; Horta, Bernardo Lessa; Hyppönen, Elina; Power, Christine; Moldovan, Max; van Iperen, Erik; Hovingh, G Kees; Demuth, Ilja; Norman, Kristina; Steinhagen-Thiessen, Elisabeth; Demuth, Juri; Bertram, Lars; Liu, Tian; Coassin, Stefan; Willeit, Johann; Kiechl, Stefan; Willeit, Karin; Mason, Dan; Wright, John; Morris, Richard; Wanamethee, Goya; Whincup, Peter; Ben-Shlomo, Yoav; McLachlan, Stela; Price, Jackie F; Kivimaki, Mika; Welch, Catherine; Sanchez-Galvez, Adelaida; Marques-Vidal, Pedro; Nicolaides, Andrew; Panayiotou, Andrie G; Onland-Moret, N Charlotte; van der Schouw, Yvonne T; Matullo, Giuseppe; Fiorito, Giovanni; Guarrera, Simonetta; Sacerdote, Carlotta; Wareham, Nicholas J; Langenberg, Claudia; Scott, Robert; Luan, Jian'an; Bobak, Martin; Malyutina, Sofia; Pająk, Andrzej; Kubinova, Ruzena; Tamosiunas, Abdonas; Pikhart, Hynek; Husemoen, Lise Lotte Nystrup; Grarup, Niels; Pedersen, Oluf; Hansen, Torben; Linneberg, Allan; Simonsen, Kenneth Starup; Cooper, Jackie; Humphries, Steve E; Brilliant, Murray; Kitchner, Terrie; Hakonarson, Hakon; Carrell, David S; McCarty, Catherine A; Kirchner, H Lester; Larson, Eric B; Crosslin, David R; de Andrade, Mariza; Roden, Dan M; Denny, Joshua C; Carty, Cara; Hancock, Stephen; Attia, John; Holliday, Elizabeth; O'Donnell, Martin; Yusuf, Salim; Chong, Michael; Pare, Guillaume; van der Harst, Pim; Said, M Abdullah; Eppinga, Ruben N; Verweij, Niek; Snieder, Harold; Christen, Tim; Mook-Kanamori, Dennis O; Gustafsson, Stefan; Lind, Lars; Ingelsson, Erik; Pazoki, Raha; Franco, Oscar; Hofman, Albert; Uitterlinden, Andre; Dehghan, Abbas; Teumer, Alexander; Baumeister, Sebastian; Dörr, Marcus; Lerch, Markus M; Völker, Uwe; Völzke, Henry; Ward, Joey; Pell, Jill P; Smith, Daniel J; Meade, Tom; Maitland-van der Zee, Anke H; Baranova, Ekaterina V; Young, Robin; Ford, Ian; Campbell, Archie; Padmanabhan, Sandosh; Bots, Michiel L; Grobbee, Diederick E; Froguel, Philippe; Thuillier, Dorothée; Balkau, Beverley; Bonnefond, Amélie; Cariou, Bertrand; Smart, Melissa; Bao, Yanchun; Kumari, Meena; Mahajan, Anubha; Ridker, Paul M; Chasman, Daniel I; Reiner, Alex P; Lange, Leslie A; Ritchie, Marylyn D; Asselbergs, Folkert W; Casas, Juan-Pablo; Keating, Brendan J; Preiss, David; Hingorani, Aroon D; Sattar, Naveed
BACKGROUND:Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with reductions in both the concentration of LDL cholesterol and the risk of coronary heart disease, but also with modest hyperglycaemia, increased bodyweight, and modestly increased risk of type 2 diabetes, which in no way offsets their substantial benefits. We sought to investigate the associations of LDL cholesterol-lowering PCSK9 variants with type 2 diabetes and related biomarkers to gauge the likely effects of PCSK9 inhibitors on diabetes risk. METHODS:, fasting insulin, bodyweight, waist-to-hip ratio, BMI, and risk of type 2 diabetes, using a standardised analysis plan, meta-analyses, and weighted gene-centric scores. FINDINGS:, -0·09 to 0·30). INTERPRETATION:PCSK9 variants associated with lower LDL cholesterol were also associated with circulating higher fasting glucose concentration, bodyweight, and waist-to-hip ratio, and an increased risk of type 2 diabetes. In trials of PCSK9 inhibitor drugs, investigators should carefully assess these safety outcomes and quantify the risks and benefits of PCSK9 inhibitor treatment, as was previously done for statins. FUNDING:British Heart Foundation, and University College London Hospitals NHS Foundation Trust (UCLH) National Institute for Health Research (NIHR) Biomedical Research Centre.
PMID: 27908689
ISSN: 2213-8595
CID: 5478542

Identifying gene-gene interactions that are highly associated with four quantitative lipid traits across multiple cohorts

De, Rishika; Verma, Shefali S; Holzinger, Emily; Hall, Molly; Burt, Amber; Carrell, David S; Crosslin, David R; Jarvik, Gail P; Kuivaniemi, Helena; Kullo, Iftikhar J; Lange, Leslie A; Lanktree, Matthew B; Larson, Eric B; North, Kari E; Reiner, Alex P; Tragante, Vinicius; Tromp, Gerard; Wilson, James G; Asselbergs, Folkert W; Drenos, Fotios; Moore, Jason H; Ritchie, Marylyn D; Keating, Brendan; Gilbert-Diamond, Diane
Genetic loci explain only 25-30 % of the heritability observed in plasma lipid traits. Epistasis, or gene-gene interactions may contribute to a portion of this missing heritability. Using the genetic data from five NHLBI cohorts of 24,837 individuals, we combined the use of the quantitative multifactor dimensionality reduction (QMDR) algorithm with two SNP-filtering methods to exhaustively search for SNP-SNP interactions that are associated with HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), total cholesterol (TC) and triglycerides (TG). SNPs were filtered either on the strength of their independent effects (main effect filter) or the prior knowledge supporting a given interaction (Biofilter). After the main effect filter, QMDR identified 20 SNP-SNP models associated with HDL-C, 6 associated with LDL-C, 3 associated with TC, and 10 associated with TG (permutation P value <0.05). With the use of Biofilter, we identified 2 SNP-SNP models associated with HDL-C, 3 associated with LDL-C, 1 associated with TC and 8 associated with TG (permutation P value <0.05). In an independent dataset of 7502 individuals from the eMERGE network, we replicated 14 of the interactions identified after main effect filtering: 11 for HDL-C, 1 for LDL-C and 2 for TG. We also replicated 23 of the interactions found to be associated with TG after applying Biofilter. Prior knowledge supports the possible role of these interactions in the genetic etiology of lipid traits. This study also presents a computationally efficient pipeline for analyzing data from large genotyping arrays and detecting SNP-SNP interactions that are not primarily driven by strong main effects.
PMID: 27848076
ISSN: 1432-1203
CID: 5478532

Genetic predisposition to elevated levels of C-reactive protein is associated with a decreased risk for preeclampsia

Spracklen, Cassandra N; Smith, Caitlin J; Saftlas, Audrey F; Triche, Elizabeth W; Bjonnes, Andrew; Keating, Brendan J; Saxena, Richa; Breheny, Patrick J; Dewan, Andrew T; Robinson, Jennifer G; Hoh, Josephine; Ryckman, Kelli K
OBJECTIVE:To examine the association between genetic predisposition to elevated C-reactive protein (CRP)and risk for preeclampsia using validated genetic loci for C-reactive protein. METHODS:Preeclampsia cases (n = 177) and normotensive controls (n = 116) were selected from live birth certificates to nulliparous Iowa women during the period August 2002-May 2005. Disease status was verified by the medical chart review. Genetic predisposition to CRP was estimated by a genetic risk score on the basis of established loci for CRP levels. Logistic regression analyses were used to evaluate the relationships between the genotype score and preeclampsia. Replication analyses were performed in an independent, US population of preeclampsia cases (n = 516) and controls (n = 1,097) of European ancestry. RESULTS:The genetic risk score (GRS) related to higher levels of CRP demonstrated a significantly decreased risk of preeclampsia (OR 0.89, 95% CI 0.82-0.96). When the GRS was analyzed by quartile, an inverse linear trend was observed (p = 0.0006). The results were similar after adjustments for the body mass index (BMI), smoking, and leisure-time physical activity. In the independent replication population, the association with the CRP GRS was also marginally significant (OR 0.97, 95% CI 0.92, 1.02). Meta-analysis of the two studies was statistically significant (OR 0.95, 95% CI 0.90, 0.99). CONCLUSION/CONCLUSIONS:Our data suggest an inverse, counterintuitive association between the genetic predisposition to elevated levels of CRP and a decreased risk of preeclampsia. This suggests that the blood CRP level is a marker of preeclampsia, but it does not appear to be a factor on the causal pathway.
PMCID:5538572
PMID: 27657194
ISSN: 1525-6065
CID: 5478522

Genome-wide Trans-ethnic Meta-analysis Identifies Seven Genetic Loci Influencing Erythrocyte Traits and a Role for RBPMS in Erythropoiesis

van Rooij, Frank J A; Qayyum, Rehan; Smith, Albert V; Zhou, Yi; Trompet, Stella; Tanaka, Toshiko; Keller, Margaux F; Chang, Li-Ching; Schmidt, Helena; Yang, Min-Lee; Chen, Ming-Huei; Hayes, James; Johnson, Andrew D; Yanek, Lisa R; Mueller, Christian; Lange, Leslie; Floyd, James S; Ghanbari, Mohsen; Zonderman, Alan B; Jukema, J Wouter; Hofman, Albert; van Duijn, Cornelia M; Desch, Karl C; Saba, Yasaman; Ozel, Ayse B; Snively, Beverly M; Wu, Jer-Yuarn; Schmidt, Reinhold; Fornage, Myriam; Klein, Robert J; Fox, Caroline S; Matsuda, Koichi; Kamatani, Naoyuki; Wild, Philipp S; Stott, David J; Ford, Ian; Slagboom, P Eline; Yang, Jaden; Chu, Audrey Y; Lambert, Amy J; Uitterlinden, André G; Franco, Oscar H; Hofer, Edith; Ginsburg, David; Hu, Bella; Keating, Brendan; Schick, Ursula M; Brody, Jennifer A; Li, Jun Z; Chen, Zhao; Zeller, Tanja; Guralnik, Jack M; Chasman, Daniel I; Peters, Luanne L; Kubo, Michiaki; Becker, Diane M; Li, Jin; Eiriksdottir, Gudny; Rotter, Jerome I; Levy, Daniel; Grossmann, Vera; Patel, Kushang V; Chen, Chien-Hsiun; Ridker, Paul M; Tang, Hua; Launer, Lenore J; Rice, Kenneth M; Li-Gao, Ruifang; Ferrucci, Luigi; Evans, Michelle K; Choudhuri, Avik; Trompouki, Eirini; Abraham, Brian J; Yang, Song; Takahashi, Atsushi; Kamatani, Yoichiro; Kooperberg, Charles; Harris, Tamara B; Jee, Sun Ha; Coresh, Josef; Tsai, Fuu-Jen; Longo, Dan L; Chen, Yuan-Tsong; Felix, Janine F; Yang, Qiong; Psaty, Bruce M; Boerwinkle, Eric; Becker, Lewis C; Mook-Kanamori, Dennis O; Wilson, James G; Gudnason, Vilmundur; O'Donnell, Christopher J; Dehghan, Abbas; Cupples, L Adrienne; Nalls, Michael A; Morris, Andrew P; Okada, Yukinori; Reiner, Alexander P; Zon, Leonard I; Ganesh, Santhi K
Genome-wide association studies (GWASs) have identified loci for erythrocyte traits in primarily European ancestry populations. We conducted GWAS meta-analyses of six erythrocyte traits in 71,638 individuals from European, East Asian, and African ancestries using a Bayesian approach to account for heterogeneity in allelic effects and variation in the structure of linkage disequilibrium between ethnicities. We identified seven loci for erythrocyte traits including a locus (RBPMS/GTF2E2) associated with mean corpuscular hemoglobin and mean corpuscular volume. Statistical fine-mapping at this locus pointed to RBPMS at this locus and excluded nearby GTF2E2. Using zebrafish morpholino to evaluate loss of function, we observed a strong in vivo erythropoietic effect for RBPMS but not for GTF2E2, supporting the statistical fine-mapping at this locus and demonstrating that RBPMS is a regulator of erythropoiesis. Our findings show the utility of trans-ethnic GWASs for discovery and characterization of genetic loci influencing hematologic traits.
PMCID:5223059
PMID: 28017375
ISSN: 1537-6605
CID: 5478552

An ectopically expressed serum miRNA signature is prognostic, diagnostic, and biologically related to liver allograft rejection

Shaked, Abraham; Chang, Bao-Li; Barnes, Michael R; Sayre, Peter; Li, Yun R; Asare, Smita; DesMarais, Michele; Holmes, Michael V; Guettouche, Toumy; Keating, Brendan J
UNLABELLED:The ability to noninvasively diagnose acute cellular rejection (ACR) with high specificity and sensitivity would significantly advance personalized liver transplant recipient care and management of immunosuppression. We performed microRNA (miRNA) profiling in 318 serum samples from 69 liver transplant recipients enrolled in the Immune Tolerance Network immunosuppression withdrawal (ITN030ST) and Clinical Trials in Organ Transplantation (CTOT-03) studies. We quantified serum miRNA at clinically indicated and/or protocol biopsy events (n = 130). The trajectory of ACR diagnostic miRNAs during immunosuppression withdrawal were also evaluated in sera taken at predetermined intervals during immunosuppression minimization before and at clinically indicated liver biopsy (n = 119). Levels of 31 miRNAs were significantly associated with ACR diagnosis with two miRNAs differentiating ACR from non-ACR (area under the receiver operating characteristic curve = 90%, 95% confidence interval = 82%-96%) and predicted ACR events up to 40 days before biopsy-proven rejection. The most differentially expressed miRNAs were low or absent in the blood of healthy individuals but highly expressed in liver tissue, indicating an ectopic origin from the liver allograft. Pathway analyses of rejection-associated miRNAs and their target messenger RNAs (mRNAs) showed induction of proinflammatory and cell death-related pathways. Integration of differentially expressed serum miRNA with concordant liver biopsy mRNA demonstrates interaction between molecules with a known role in transplant rejection. CONCLUSION:Distinct miRNA levels profiled from sera at the time of clinical allograft dysfunction can be used to noninvasively diagnose ACR. Predictive trajectories of the same profile during supervised immunosuppression minimization diagnosed rejection up to 40 days prior to clinical expression. The rejection-associated miRNAs in sera appear to be ectopically expressed liver and specific immune cell miRNAs that are biologically related, and the consequences of immune-mediated damage to the allograft. (Hepatology 2017;65:269-280).
PMID: 27533743
ISSN: 1527-3350
CID: 5478492

Whole Exome Sequencing Identifies the Genetic Basis of Late-Onset Leigh Syndrome in a Patient with MRI but Little Biochemical Evidence of a Mitochondrial Disorder

Nafisinia, Michael; Guo, Yiran; Dang, Xiao; Li, Jiankang; Chen, Yulan; Zhang, Jianguo; Lake, Nicole J; Gold, Wendy A; Riley, Lisa G; Thorburn, David R; Keating, Brendan; Xu, Xun; Hakonarson, Hakon; Christodoulou, John
Leigh syndrome is a subacute necrotising encephalomyopathy proven by post-mortem analysis of brain tissue showing spongiform lesions with vacuolation of the neuropil followed by demyelination, gliosis and capillary proliferation caused by mutations in one of over 75 different genes, including nuclear- and mitochondrial-encoded genes, most of which are associated with mitochondrial respiratory chain function. In this study, we report a patient with suspected Leigh syndrome presenting with seizures, ptosis, scoliosis, dystonia, symmetrical putaminal abnormalities and a lactate peak on brain MRS, but showing normal MRC enzymology in muscle and liver, thereby complicating the diagnosis. Whole exome sequencing uncovered compound heterozygous mutations in NADH dehydrogenase (ubiquinone) flavoprotein 1 gene (NDUFV1), c.1162+4A>C (NM_007103.3), resulting in skipping of exon 8, and c.640G>A, causing the amino acid substitution p.Glu214Lys, both of which have previously been reported in a patient with complex I deficiency. Patient fibroblasts showed a significant reduction in NDUFV1 protein expression, decreased complex CI and complex IV assembly and consequential reductions in the enzymatic activities of both complexes by 38% and 67%, respectively. The pathogenic effect of these variations was further confirmed by immunoblot analysis of subunits for MRC enzyme complexes in patient muscle, liver and fibroblast where we observed 90%, 60% and 95% reduction in complex CI, respectively. Together these studies highlight the importance of a comprehensive, multipronged approach to the laboratory evaluation of patients with suspected Leigh syndrome.
PMCID:5362551
PMID: 27344648
ISSN: 2192-8304
CID: 5478472

GENOME-WIDE ASSOCIATION STUDY IDENTIFIES NOVEL RISK LOCI FOR ACUTE KIDNEY TRANSPLANT REJECTION [Meeting Abstract]

Yang, Jianxin; Dreyer, Geertje J.; van Setten, Jessica; de Fijter, Hans W.; Keating, Brendan J.; Claas, Frans H. J.; Eikmans, Michael
ISI:000400973300021
ISSN: 2059-2302
CID: 5479132

Discovery and replication of SNP-SNP interactions for quantitative lipid traits in over 60,000 individuals

Holzinger, Emily R; Verma, Shefali S; Moore, Carrie B; Hall, Molly; De, Rishika; Gilbert-Diamond, Diane; Lanktree, Matthew B; Pankratz, Nathan; Amuzu, Antoinette; Burt, Amber; Dale, Caroline; Dudek, Scott; Furlong, Clement E; Gaunt, Tom R; Kim, Daniel Seung; Riess, Helene; Sivapalaratnam, Suthesh; Tragante, Vinicius; van Iperen, Erik P A; Brautbar, Ariel; Carrell, David S; Crosslin, David R; Jarvik, Gail P; Kuivaniemi, Helena; Kullo, Iftikhar J; Larson, Eric B; Rasmussen-Torvik, Laura J; Tromp, Gerard; Baumert, Jens; Cruickshanks, Karen J; Farrall, Martin; Hingorani, Aroon D; Hovingh, G K; Kleber, Marcus E; Klein, Barbara E; Klein, Ronald; Koenig, Wolfgang; Lange, Leslie A; Mӓrz, Winfried; North, Kari E; Charlotte Onland-Moret, N; Reiner, Alex P; Talmud, Philippa J; van der Schouw, Yvonne T; Wilson, James G; Kivimaki, Mika; Kumari, Meena; Moore, Jason H; Drenos, Fotios; Asselbergs, Folkert W; Keating, Brendan J; Ritchie, Marylyn D
BACKGROUND:The genetic etiology of human lipid quantitative traits is not fully elucidated, and interactions between variants may play a role. We performed a gene-centric interaction study for four different lipid traits: low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), and triglycerides (TG). RESULTS: < 0.001 in the discovery dataset were tested for replication. We identified thirteen SNP-SNP models that were significant in more than one replication cohort after accounting for multiple testing. CONCLUSIONS:These results may reveal novel insights into the genetic etiology of lipid levels. Furthermore, we developed a pipeline to perform a computationally efficient interaction analysis with multi-cohort replication.
PMCID:5525436
PMID: 28770004
ISSN: 1756-0381
CID: 5478572

Adult height, coronary heart disease and stroke: a multi-locus Mendelian randomization meta-analysis

Nüesch, Eveline; Dale, Caroline; Palmer, Tom M; White, Jon; Keating, Brendan J; van Iperen, Erik Pa; Goel, Anuj; Padmanabhan, Sandosh; Asselbergs, Folkert W; Verschuren, W M; Wijmenga, C; Van der Schouw, Y T; Onland-Moret, N C; Lange, Leslie A; Hovingh, G K; Sivapalaratnam, Suthesh; Morris, Richard W; Whincup, Peter H; Wannamethe, Goya S; Gaunt, Tom R; Ebrahim, Shah; Steel, Laura; Nair, Nikhil; Reiner, Alexander P; Kooperberg, Charles; Wilson, James F; Bolton, Jennifer L; McLachlan, Stela; Price, Jacqueline F; Strachan, Mark Wj; Robertson, Christine M; Kleber, Marcus E; Delgado, Graciela; März, Winfried; Melander, Olle; Dominiczak, Anna F; Farrall, Martin; Watkins, Hugh; Leusink, Maarten; Maitland-van der Zee, Anke H; de Groot, Mark Ch; Dudbridge, Frank; Hingorani, Aroon; Ben-Shlomo, Yoav; Lawlor, Debbie A; Amuzu, A; Caufield, M; Cavadino, A; Cooper, J; Davies, T L; Drenos, F; Engmann, J; Finan, C; Giambartolomei, C; Hardy, R; Humphries, S E; Hypponen, E; Kivimaki, M; Kuh, D; Kumari, M; Ong, K; Plagnol, V; Power, C; Richards, M; Shah, S; Shah, T; Sofat, R; Talmud, P J; Wareham, N; Warren, H; Whittaker, J C; Wong, A; Zabaneh, D; Davey Smith, George; Wells, Jonathan C; Leon, David A; Holmes, Michael V; Casas, Juan P
BACKGROUND:We investigated causal effect of completed growth, measured by adult height, on coronary heart disease (CHD), stroke and cardiovascular traits, using instrumental variable (IV) Mendelian randomization meta-analysis. METHODS:We developed an allele score based on 69 single nucleotide polymorphisms (SNPs) associated with adult height, identified by the IBCCardioChip, and used it for IV analysis against cardiovascular risk factors and events in 21 studies and 60 028 participants. IV analysis on CHD was supplemented by summary data from 180 height-SNPs from the GIANT consortium and their corresponding CHD estimates derived from CARDIoGRAMplusC4D. RESULTS:IV estimates from IBCCardioChip and GIANT-CARDIoGRAMplusC4D showed that a 6.5-cm increase in height reduced the odds of CHD by 10% [odds ratios 0.90; 95% confidence intervals (CIs): 0.78 to 1.03 and 0.85 to 0.95, respectively],which agrees with the estimate from the Emerging Risk Factors Collaboration (hazard ratio 0.93; 95% CI: 0.91 to 0.94). IV analysis revealed no association with stroke (odds ratio 0.97; 95% CI: 0.79 to 1.19). IV analysis showed that a 6.5-cm increase in height resulted in lower levels of body mass index ( P  < 0.001), triglycerides ( P  < 0.001), non high-density (non-HDL) cholesterol ( P  < 0.001), C-reactive protein ( P  = 0.042), and systolic blood pressure ( P  = 0.064) and higher levels of forced expiratory volume in 1 s and forced vital capacity ( P  < 0.001 for both). CONCLUSIONS:Taller individuals have a lower risk of CHD with potential explanations being that taller people have a better lung function and lower levels of body mass index, cholesterol and blood pressure.
PMCID:5841831
PMID: 25979724
ISSN: 1464-3685
CID: 5478322